Catalent - CTLT Stock Forecast, Price & News

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. Catalent, Inc. was incorporated in 2007 and is headquartered in Somerset, New Jersey.

Wall Street Analysts Forecast Growth

Separately, Deutsche Bank Aktiengesellschaft cut their target price on shares of Catalent from $129.00 to $110.00 and set a "hold" rating on the stock in a research report on Tuesday, April 12th. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to MarketBeat.com, Catalent presently has an average rating of "Moderate Buy" and an average target price of $142.86.

Catalent Stock Down 1.7 %

Shares of Catalent stock traded down $1.91 on Tuesday, reaching $108.13. The stock had a trading volume of 607,367 shares, compared to its average volume of 1,199,303. The company has a 50 day moving average price of $107.51 and a 200 day moving average price of $103.12. The company has a quick ratio of 2.25, a current ratio of 2.89 and a debt-to-equity ratio of 0.90. Catalent has a 1 year low of $86.34 and a 1 year high of $142.64. The stock has a market capitalization of $19.38 billion, a P/E ratio of 39.18, a P/E/G ratio of 1.68 and a beta of 1.29.

Insider Transactions at Catalent

In other news, CEO Alessandro Maselli sold 816 shares of Catalent stock in a transaction that occurred on Tuesday, July 26th. The shares were sold at an average price of $106.90, for a total value of $87,230.40. Following the transaction, the chief executive officer now owns 25,083 shares of the company's stock, valued at approximately $2,681,372.70. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Catalent news, CEO Alessandro Maselli sold 816 shares of the business's stock in a transaction that occurred on Tuesday, July 26th. The shares were sold at an average price of $106.90, for a total transaction of $87,230.40. Following the sale, the chief executive officer now owns 25,083 shares of the company's stock, valued at approximately $2,681,372.70. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Thomas P. Castellano sold 347 shares of the business's stock in a transaction that occurred on Tuesday, July 26th. The stock was sold at an average price of $106.90, for a total transaction of $37,094.30. Following the sale, the chief financial officer now directly owns 15,051 shares in the company, valued at approximately $1,608,951.90. The disclosure for this sale can be found here. Insiders have sold a total of 4,462 shares of company stock valued at $476,951 in the last 90 days. Insiders own 0.53% of the company's stock.